<span item_type="fundamental" item_id="b91aa50f0bd4488fc5505da6c5747db4" counter_id="ETF/US/FLAG" env="prod"></span><span item_type="announcement" item_id="582440827760284929" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.21.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -5.13 M.</p><p></p><h3>Net Loss</h3><ul><li>The company reported a net loss of $5.2 million for the three months ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024. A non-cash charge for deemed dividend on warrants increased the net loss attributable to shareholders to $10.8 million in 2025, with no such charge in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Research and development expenses were $2.4 million for the three months ended September 30, 2025, compared to $2.2 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li><li>General and administrative expenses were $2.7 million for the three months ended September 30, 2025, compared to $3.1 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li></ul><h3>Cash and Cash Equivalents</h3><ul><li>The company had approximately $10.4 million in cash and $0.2 million in restricted cash as of September 30, 2025, compared to $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li></ul><h3>Total Liabilities and Equity</h3><ul><li>Total liabilities were $6.8 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li><li>Total equity was $7.2 million as of September 30, 2025, compared to $2.0 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Calidi Biotherapeutics anticipates continued progress in its clinical trials and development of therapeutic candidates, although it acknowledges risks related to capital raising and potential changes in clinical outcomes as more data becomes available.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/ex99-1.htm"></span></li></ul>

Global X S&P 500 U.S. Mkt Ldr TOP 50 ETF | 8-K: FY2025 Q3 Revenue: USD 0